OncoSec Medical Appoints Sharron Gargosky, PhD, As Head Of Clinical Development And Operations

SAN DIEGO, Feb. 29, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Sharron Gargosky, PhD, as Head of Clinical Development and Operations.

"Dr. Gargosky's deep expertise in clinical operations and development will significantly contribute to the strength of OncoSec's management team to move our clinical programs forward, prioritize our product development strategy, and identify opportunities to leverage ImmunoPulse to address a significant unmet medical need in oncology," said Punit Dhillon, President and CEO of OncoSec. "We're excited for Dr. Gargosky to apply her unique background and expertise as a consultant to advance our clinical programs towards commercialization."     

Dr. Gargosky has over 20 years of experience in clinical development and operations in the field of pharmaceutical and biologic development having managed global programs from early research phase through the U.S. Food & Drug Administration (FDA) approval process. Recently, Dr. Gargosky was the Chief Technical and Operations Officer at Prima Biomed, Ltd., where she led the immuno-oncology program in ovarian and pancreatic cancer overseeing international manufacturing, regulatory approvals, and clinical execution. Prior to Prima Biomed, Dr. Gargosky served in positions of increasing clinical and scientific responsibility at biopharmaceutical companies including Pharmacia, Medicis, and Hyperion Therapeutics. In her career, she was involved in small molecule development attaining orphan drug approvals in rare diseases. Dr. Gargosky received her PhD from the University of Adelaide, Australia and completed her postdoctoral fellowship at Stanford University.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

Media Relations:
Mary Marolla
OncoSec Medical Incorporated
[email protected]

OncoSec Medical, Inc. Logo. Please visit http://oncosec.com/ for more information.
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-appoints-sharron-gargosky-phd-as-head-of-clinical-development-and-operations-300227456.html

SOURCE OncoSec Medical Incorporated